Diabetes and end-stage renal disease; a review article on new concepts

Seyed Bahman Ghaderian, Fatemeh Hayati, Shokouh Shayanpour, Seyed Seifollah Beladi Mousavi, Seyed Bahman Ghaderian, Fatemeh Hayati, Shokouh Shayanpour, Seyed Seifollah Beladi Mousavi

Abstract

It is well established that diabetic nephropathy is the most common cause or in combination with hypertensive nephropathy are the most common causes of end-stage renal disease (ESRD) in developed and developing countries. For this review, we used a variety of sources by searching through PubMed, Embase, Scopus, Current Content and Iran Medex from January 1990 up to December 2014. Manuscripts published in English and Persian languages, as full-text articles, and or as abstract were included in the study. Patient survival in diabetics on maintenance renal replacement therapy including hemodialysis (HD), peritoneal dialysis (PD) and kidney transplantation is significantly lower than that seen in nondiabetics with ESRD. The poor prognosis of diabetic patients with ESRD is partly due to presence of significant cardiovascular disease, problems with vascular access, more susceptible to infections, foot ulcer, and hemodynamic instability during HD. Although, many complications related to kidney transplantation may occur in diabetic ESRD patients, multiple studies have found that the kidney transplantation is the preferred renal replacement therapy for diabetic patients with ESRD and it is associated with a much better survival and quality of life than dialysis among these patients.

Keywords: Diabetic nephropathy; End-stage renal disease; Hemodialysis; Renal replacement therapy.

References

    1. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med. 1999;341:1127.
    1. Krolewski M, Eggers PW, Warram JH. Magnitude of end-stage renal disease in IDDM: a 35 year follow-up study. Kidney Int. 1996;50:2041.
    1. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med. 1999;341:1127.
    1. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–60.
    1. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.
    1. Ghorbani A, Omidvar B, Beladi-Mousavi SS, Lak E, Vaziri S. The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial. Nefrologia. 2012;32(6):790–6.
    1. Arefzadeh A, Lessanpezeshki M, Seifi S. The cost of hemodialysis in Iran. Saudi J Kidney Dis Transpl. 2009;20(2):307–11.
    1. Beladi Mousavi SS, Sametzadeh M, Hayati F, Fatemi SM. Evaluation of acquired cystic kidney disease in patients on hemodialysis with ultrasonography. Iran J Kidney Dis. 2010;4(3):223–6.
    1. Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis. 1999;34:795–808.
    1. USRDS: The United States Renal Data System. Excerpts from the USRDS 2009 annual data report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis. 2010;55(Suppl 1):S1.
    1. Atkins RC. The epidemiology of chronic kidney disease. Kidney Int. 2005;67:14–18.
    1. Sørensen VR, Hansen PM, Heaf J, Feldt-Rasmussen B. Stabilized incidence of diabetic patients referred for renal replacement therapy in Denmark. Kidney Int. 2006;70:187.
    1. Beladi Mousavi SS, Hayati F, Talebnejad M, Mousavi M. What is the Difference between Causes of ESRD in Iran and Developing Countries? SEMJ. 2012;2:13.
    1. Ghaderian SB, Beladi-Mousavi SS. The role of diabetes and hypertension in chronic kidney disease. J Renal Inj Prev. 2014;3(4):109–110.
    1. Aghighi M, Mahdavi-Mazdeh M, Zamyadi M, Heidary RA, Rajolani H, Nourozi S. Changing epidemiology of end-stage renal disease in last 10 years in Iran. Iran J Kidney Dis. 2009;3(4):192–6.
    1. Beladi Mousavi SS, Beladi Mousavi M, Hayati F, Talebzadeh M. Effect of Intranasal DDAVP in Prevention of Hypotension during Hemodialysis. Nefrologia. 2012;32(1):89–93.
    1. Al Wakeel JS, Mitwalli AH, Al Mohaya S, Abu-Aisha H, Tarif N, Malik GH. et al. Morbidity and Mortality in ESRD Patients on Dialysis. Saudi J Kidney Dis Transpl. 2002;13:473–7.
    1. Al-Khader AA. Impact of diabetes in renal diseases in Saudi Arabia. Nephrol Dial Transplant. 2001;16(11):2132–5.
    1. Barsoum R. Nephrology in Egypt: A Forecast of the Upcoming Century. .
    1. Almdal Almdal, T T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med. 2004;164:1422–6.
    1. The United States Renal Data System. Excerpts from the USRDS 2008 annual data report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis. 2009;53:S1.
    1. Beladi Mousavi SS, Alemzadeh Ansari MJ, Cheraghian B. Outcome of patients on hemodialysis in Khuzestan, Iran. NDT Plus. 2011;4(2):143–4.
    1. Cooper L. USRDS 2001 Annual Data Report. Nephrol News Issues. 2001;15(10):31, 34–35, 38.
    1. Lok CE, Oliver MJ, Rothwell DM, Hux JE. The growing volume of diabetes-related dialysis: a population based study. Nephrol Dial Transplant. 2004;19:3098–103.
    1. Beladi Mousavi SS, Hayati F, Alemzadeh Ansari MJ, Valavi E. Survival at 1, 3, and 5 years in diabetic and nondiabetic patients on hemodialysis. Iran J Kidney Dis. 2010;4:74–7.
    1. McMillan MA, Briggs JD, Junor BJ. Outcome of renal replacement treatment in patients with diabetes mellitus. BMJ. 1990;301:540–4.
    1. Beladi Mousavi SS, Alemzadeh Ansari MJ, Alemzadeh Ansari MH, BeladiMousavi M. Long-term survival of patients with end-stage renal disease on maintenance hemodialysis A multicenter study in Iran. Iran J Kidney Dis. 2012;6:452–6.
    1. Schroijen MA, van de Luijtgaarden MW, Noordzij M, Ravani P, Jarraya F, Collart F. et al. Survival in dialysis patients is different between patients with diabetes as primary renal disease and patients with diabetes as a co-morbid condition. Diabetologia. 2013;56:1949–57.
    1. Goldstein A, Kliger AS, Finkelstein FO. Recovery of renal function and the discontinuation of dialysis in patients treated with continuous peritoneal dialysis. Perit Dial Int. 2003;23:151.
    1. Teitelbaum I, Burkart J. Peritoneal dialysis. Am J Kidney Dis. 2003;42:1082.
    1. Tamadon MR, Beladi-Mousavi SS. Erythropoietin; a review on current knowledge and new concepts. J Renal Inj Prev. 2013;2:119–21.
    1. Wauters JP, Uehlinger D. Non-medical factors influencing peritoneal dialysis utilization: the Swiss experience. Nephrol Dial Transplant. 2004;19:1363.
    1. Beladi Mousavi SS, Tavazoe M, Hayati F, Sametzadeh M. Arterio-Venous fistula recirculation in hemodialysis: causes and prevalences. Shiraz E-Medical Journal. 2010;11:219–24.
    1. Mendelssohn DC, Langlois N, Blake PG. Peritoneal dialysis in Ontario: a natural experiment in physician reimbursement methodology. Perit Dial Int. 2004;24:531–7.
    1. Shoji T, Tsubakihara Y, Fujii M, Imai E. Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int. 2004;66:1212–20.
    1. Henrich WL. Hemodynamic instability during hemodialysis. Kidney Int. 1986;30:605–12.
    1. McDonald SP, Marshall MR, Johnson DW, Polkinghorne KR. Relationship between dialysis modality and mortality. J Am Soc Nephrol. 2009;20:155–63.
    1. Foley RN, Parfrey PS, Harnett JD. Mode of dialysis therapy and mortality in end-stage renal disease. J Am Soc Nephrol. 1998;9:267–76.
    1. U S. Renal Data System. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2009
    1. Rabbat CG, Thorpe KE, Russell JD, Churchill DN. Comparison of mortality risk for dialysis patients and cadaveric first renal transplant recipients in Ontario, Canada. J Am Soc Nephrol. 2000;11:917–22.
    1. Oniscu GC, Brown H, Forsythe JL. Impact of cadaveric renal transplantation on survival in patients listed for transplantation. J Am Soc Nephrol. 2005;16:1859–65.
    1. Gill JS, Tonelli M, Johnson N, Pereira BJ. Why do preemptive kidney transplant recipients have an allograft survival advantage? Transplantation. 2004;78:873–9.
    1. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY. et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341:1725–30.
    1. Lentine KL, Rocca Rey LA, Kolli S, Bacchi G, Schnitzler MA, Abbott KC. et al. Variations in the risk for cerebrovascular events after kidney transplant compared with experience on the waiting list and after graft failure. Clin J Am Soc Nephrol. 2008;3:1090–1101.
    1. Meier-Kriesche HU, Port FK, Ojo AO, Rudich SM, Hanson JA, Cibrik DM. et al. Effect of waiting time on renal transplant outcome. Kidney Int. 2000;58:1311–7.
    1. Becker BN, Rush SH, Dykstra DM, Becker YT, Port FK. Preemptive transplantation for patients with diabetes-related kidney disease. Arch Intern Med. 2006;166:44–8.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다